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Abstract
Background: DC are activated by pathogen-associated molecular patterns (PAMPs), and this is pivotal for the induction of
adaptive immune responses. Thereafter, the clearance of activated DC is crucial to prevent immune pathology. While PAMPs
are of major interest for vaccine science due to their adjuvant potential, it is unclear whether and how PAMPs may affect DC
viability. We aimed to elucidate the possible apoptotic mechanisms that control activated DC lifespan in response to PAMPs,
particularly in vivo.
Methodology/Principal Findings: We report that polyinosinic:polycytidylic acid (PolyIC, synthetic analogue of dsRNA)
induces dramatic apoptosis of mouse splenic conventional DC (cDC) in vivo, predominantly affecting the CD8a subset, as
shown by flow cytometry-based analysis of splenic DC subsets. Importantly, while Bim deficiency conferred only minor
protection, cDC depletion was prevented in mice lacking Bim plus one of three other BH3-only proteins, either Puma, Noxa
or Bid. Furthermore, we show that Type I Interferon (IFN) is necessary and sufficient for DC death both in vitro and in vivo,
and that TLR3 and MAVS co-operate in IFNß production in vivo to induce DC death in response to PolyIC.
Conclusions/Significance: These results demonstrate for the first time in vivo that apoptosis restricts DC lifespan following
activation by PolyIC, particularly affecting the CD8a cDC subset. Such DC apoptosis is mediated by the overlapping action of
pro-apoptotic BH3-only proteins, including but not solely involving Bim, and is driven by Type I IFN. While Type I IFNs are
important anti-viralfactors,CD8a cDCaremajorcross-presentingcellsandcriticalinducersofCTL. Wediscusssuch paradoxical
finding on DC death with PolyIC/Type I IFN. These results could contribute to understand immunosuppression associated with
chronic infection, and to the optimization of DC-based therapies and the clinical use of PAMPs and Type I IFNs.
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Introduction
Dendritic cells (DC) are the most potent professional antigen-
presenting cells and play a key role in the induction of tolerance
and initiation of adaptive immune responses [1]. Such decisive
role of DC has attracted major attention for the improvement of
vaccine efficacy, including the targeting of antigens to DC and the
use of adjuvants to optimally activate DC and consequently boost
immunity [2].
The DC system is composed of phenotypically and functionally
heterogeneous subsets [1,3]. Migratory DC reside in non-lymphoid
organs and are able to capture antigens at the sites of infection or
injury and transport them to draining lymph nodes. Lymphoid
tissue-resident, conventional DC (cDC) are non-migratory and
serve as sentinels in secondary lymphoid organs and tissues for in situ
antigen capture and presentation. In the mouse, several DC
subtypes can be found in the spleen: two subsets of cDC (CD8a
+
CD11b
2 and CD8
2 CD11b
+, hereafter termed CD8a and CD11b
subsets), inflammatory monocyte-derived DC, and plasmacytoid
DC (pDC).
Pattern-Recognition Receptors (PRR), including the Toll like
receptor (TLR) family, detect Pathogen-Associated Molecular
Patterns (PAMPs) and are important for the stimulation of
antigen-presenting activity, featuring up-regulation of co-stimula-
tory molecules and the secretion of a variety of chemokines and
cytokines [4]. Importantly, following detection of PAMPs, DC
switch from tolerance induction to T cell priming. Notably, the
various DC subsets differ in their profile of PRR expression as well
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20189as in their cytokine responses and antigen-presenting capacities,
with a consequent division of labour amongst DC subsets in
pathogen recognition and immune response initiation [4,5].
Amongst the different PAMPs under research and used in clinical
studies, the synthetic dsRNA analog polyinosinic:polycytidylic acid
(PolyIC) has proven superiority as a vaccine adjuvant for Th1
immunity, including in DC targeted vaccines [2], with the
induction of Type I Interferon (IFN) by PolyIC being key to the
enhancement of DC function [6].
The control of DC lifespan is yet another critical parameter
that can profoundly influence the outcome of an immune
response, potentially affecting vaccine efficacy and its side-effects
[7,8]. While an increase in the lifespan of DC can elicit
autoimmunity [9], reduced DC numbers correlate with immu-
nosuppressed states in several settings both in humans and in
mice, including chronic viral infection, sepsis and cancer [7]. The
DC compartment must be strictly regulated, in order to sustain
homeostasis, to return to steady-state levels following the
induction of an immune response, to prevent autoimmunity,
and to avoid immunosuppresion.
Apoptotic cell death is thought to play a critical role in the
regulation of the numbers and function of DC [7,8]. Mammals
have two distinct but ultimately converging apoptosis signaling
pathways. The ‘‘death receptor’’ (or ‘‘extrinsic’’) pathway is
triggered by members of the TNF-R family, containing intra-
cellular ‘‘death domains’’ (e.g. Fas, TNF-R1), and requires
activation of the initiator caspase, caspase-8. The ‘‘Bcl-2-
regulated’’ (also called ‘‘intrinsic’’ or ‘‘mitochondrial’’) apoptotic
pathway can be triggered by developmental cues, cytokine
withdrawal or cytotoxic stress signals (e.g. DNA damage); it
involves mitochondrial outer membrane permeabilization
(MOMP) and consequent release of apoptogenic factors, such as
cytochrome c, which promotes activation of the initiator caspase-9,
unleashing the caspase cascade. This pathway is controlled by the
Bcl-2 family and these proteins can be sub-divided according to
structure and function [10]. The anti-apoptotic members,
including Bcl-2, Bcl-xL, Mcl-1 and A1, share up to 4 regions of
homology (BH or Bcl-2 Homology domains) and are essential for
cell survival. Bax and Bak have three BH regions and are critical
for MOMP and activation of the effector phase of apoptosis. The
BH3-only subgroup, including Bim, Bid, Puma and Noxa, is
essential for initiation of apoptosis and thought to activate Bax/
Bak proteins either directly or indirectly by sequestering their pro-
survival relatives [11]. Both the ‘‘death receptor’’ and the ‘‘Bcl-2-
regulated’’ apoptotic pathways converge upon the activation of the
effector caspases, caspase-3, -6 and -7, which cleave a multitude of
substrates and thereby cause cellular demolition. In addition,
cross-talk between ‘‘intrinsic’’ and ‘‘extrinsic’’ apoptosis pathways
may occur. For instance, caspase-8 may proteolytically activate the
pro-apoptotic BH3-only member Bid that will then activate the
‘‘intrinsic’’, mitochondrial death pathway.
The apoptotic mechanisms that regulate DC function are
poorly understood. T-cell dependent killing of antigen-presenting
DC has been described for both CD4 and CD8 T cells, via FasL
and perforin secretion, respectively, as a negative feedback
mechanism to attenuate immune responses [12,13]. However,
there is incomplete or contradictory evidence on the consequences
of microbial stimulation for DC viability. Treatment of DC in vitro
with TLR-Ls results in up-regulation of the pro-apoptotic protein
Bim, but TLR-Ls rather promote survival and appear to have an
inhibitory effect on the spontaneous apoptosis of DC in culture
[14]. Furthermore, Bim-deficient DC are partially protected from
spontaneous apoptosis in vitro, regardless of the presence or
absence of TLR-Ls [14]. In contrast, treatments in vivo using TLR-
Ls, such as CpG or LPS, as well as infection with E.coli or LCMV-
Armstrong, induce loss of splenic cDC [15,16]. To date, there is a
lack of information on the possible apoptotic pathways that control
DC populations during the early phases of activation in vivo,
particularly in response to PAMPs and independently of other
immune cells.
Here we show that PolyIC induces apoptosis of splenic cDC
following their activation in vivo,w i t ht h eC D 8 a cDC being more
susceptible than the CD11b cDC subset. Proving the apoptotic
mechanism involved in vivo, absence of Bim together with a
second BH3-only family member (Bid, Noxa or Puma) leads to
protection from DC death. We also show that Type I IFN
production is required and sufficient for PolyIC-induced DC
death. This study sheds light into the mechanisms of activated
DC death in vivo. The results could contribute to an understand-
ing of immunosuppression during chronic viral infection and
inflammation, and may provide important clues for the
optimization of vaccines and treatments featuring PAMPs and
Type I IFNs.
Results
Splenic cDC are reduced in numbers following PolyIC
treatment
Splenic cDC were analyzed at several time-points following
injection of PolyIC in WT mice. In spleen, cDC are characterized
as CD11c MHC-II B220
2 and are commonly divided into the
CD8a
+ CD24
+ CD11b
2 SIRPa
2 and CD8
2 CD24
2 CD11b
+
SIRPa
+ subsets with a steady-state ratio of 1:3 [3]. The other
major DC subset, the pDC, expresses intermediate levels of
CD11c and is B220
+. Moreover, infiltrating monocytes can
differentiate into DC expressing CD11c and Gr-1 (moDC). We
therefore identified splenic cDC as CD11c
+ B220
2 Gr-1
2 and
sub-divided them into CD8a or CD11b subsets. As expected,
PolyIC induced cDC activation, characterized by up-regulation of
the co-stimulatory molecules CD40, CD80 and CD86, with a peak
between 10–20 h (Fig. 1A). Activation was more pronounced in
the CD8a subset and correlated with a marked increase in their
absolute numbers at 10 h (Fig. 1B). Between 40 and 100 h,
however, the CD8a subset was dramatically reduced in numbers,
with as little as 10% remaining when compared to starting
numbers (Fig. 1B and C). In comparison, the CD11b subset
showed a less pronounced activation as well as less expansion and
subsequent reduction. Within 130 h of PolyIC treatment, both
cDC subsets returned to steady-state levels. These results
demonstrate that, in response to PolyIC injection, splenic cDC
undergo transient activation followed by a marked reduction in the
CD8a cDC subset in vivo.
Splenic cDC depletion upon PolyIC stimulation is
independent of both T cells and NK cells
Previous reports have described the killing of DC by both CD4
and CD8 T cells, via Fas ligand and perforin, respectively [12,13].
Splenic cDC depletion was therefore investigated in the Fas
LPR
spontaneous mutant (Fas-deficient) mice and perforin (Pfn)-
deficient mice at 40 h of PolyIC treatment. In neither case was
the loss of splenic cDC prevented (Fig. 2A), showing that the
previously described CD4 and CD8 T cell controls of DC
populations by these factors are not involved in PolyIC-induced
splenic cDC depletion. To further evaluate the contribution of NK
cells and/or T cells in this loss of splenic cDC, we injected PolyIC
into mice lacking both cell types due to deficiency in Rag-2 and
the cytokine receptor common c-chain (cc)( Rag-2
2/2cc
2/2)
(Fig. 2B and Fig. S1A). Treatment of Rag-2
2/2cc
2/2 mice with
PolyIC Kills DC via Type I IFN/BH3-Only Proteins
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cDC (Fig. S1B). The fold-change in total cells with PolyIC
showed that CD8a cDC were more extensively depleted, while
CD11b cDC were less reduced, in Rag2
2/2cc
2/2 mice compared
to WT mice (Fig. 2B). Interestingly, Rag-2
2/2cc
2/2 mice showed
a steady-state CD8a-to-CD11b cDC ratio close to 0.8, in contrast
to WT mice which display a ratio of ,0.3. Such altered ratio is
seen in all mice lacking B cells (K.S. and D.V., unpublished
Figure 1. Kinetics of PolyIC-induced activation and loss of splenic cDC subsets. Mice were injected for several lengths of time with PolyIC
(n=3 per time-point) or PBS (time-points 0, 10, 70 or 130 h) as controls. A. The geometric mean of fluorescence intensity (GeoMFI) is shown for the
activation markers CD40, CD80 and CD86 within each splenic cDC subset analyzed as in C. B. Total cells from each cDC subset per time-point as
indicated. P-values indicate significance per time-point compared to injection with PBS. C. Gating strategy for the analysis of splenic cDC subsets,
showing one representative sample. Splenic leukocytes were gated for CD11c B220
2Gr-1
2 cDC (R1xR2), and further segregated into CD8a or CD11b
subsets. Data are representative of at least two independent experiments (except for time-point 130h).
doi:10.1371/journal.pone.0020189.g001
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upon PolyIC treatment in Rag-2
2/2cc
2/2.
Regardless, these results demonstrate that a T cell- and NK cell-
independent mechanism must reduce spleen cDC numbers and
thereby limit DC responses to PolyIC stimulation.
Depletion of splenic cDC also occurs upon treatment
with different TLR-Ls and pathogenic infection
It has been shown that both CpG (TLR9-L) and LPS (TLR4-
L) induce loss of splenic DC, albeit with limited distinction and
quantitation of DC subsets [15]. We therefore examined
whether preferential depletion of CD8a cDC was unique to
P o l y I C ,o rw h e t h e ri tc o u l da l s ob eo b s e r v e dw i t ho t h e rP A M P s .
At 12 h, both CpG and LPS induced activation of the two cDC
subsets (Fig. S2A), as well as a reduction in their cell numbers at
40 h (Fig. S2B). Interestingly, as in the case of PolyIC, LPS and
CpG induced a greater activation and cDC loss in CD8a cDCs
compared to CD11b cDCs. While CpG induced more modest
effects, LPS treatment caused an extent of activation and
subsequent depletion of CD8a cDCs comparable to PolyIC.
PolyIC is a synthetic dsRNA analog that mimics genome or
replication intermediates often found in viruses. In order to
examine whether cDC depletion also occurs during infection with
live pathogens in vivo, we analyzed the splenic cDC composition in
mice at early time-points following challenge with LCMV or
Leishmania parasites. Infection with 209000 pfu of LCMV-
Armstrong has previously been shown to reduce the numbers of
both splenic cDC subsets by ,50% at day 3 [16]. In our study, we
inoculated mice i.v. with 109000 pfu of LCMV-WE, a more
aggressive and persistent strain of LCMV [17]. Early activation
(CD86) on day 2 was accompanied by partial loss of cDC, and
even more profound loss was observed on day 3 (Fig. 3A). Again,
the CD8a cDC subset was more severely affected than the CD11b
subset. Compared to the previously reported data on LCMV-
Armstrong infection [16], the more aggressive LCMV-WE strain
induced a bigger loss of cDC.
In addition, we challenged mice with the two Leishmania species,
L. major and L. guyanensis, causing cutaneous and mucocutaneous
leishmaniasis, respectively. Leishmania parasites stimulate surface as
well as endosomal TLRs. Interestingly, L. guyanensis harbors a
dsRNA virus that can provide additional TLR-3 stimulation [18],
similar to PolyIC. Systemic infection of mice with L. major or L.
guyanensis resulted in activation (CD86) of both cDC subsets on
days 2 and 3 (Fig. 3B). Significant loss of splenic cDC was only
observed with L. guyanensis but not L. major, presumably due to the
stimulation by leishmaniavirus carried in L. guyanensis (additio-
nalTLR3-L component).
Altogether, these data show that loss of splenic cDC was not
restricted to stimulation with synthetic PolyIC but was also found
in more patho-physiologically relevant infectious settings.
PolyIC modulates expression of pro- and anti-apoptotic
Bcl-2 family genes in splenic cDCs in vivo
Given the dramatic loss of splenic cDC upon PolyIC treatment,
independently of other immune cells, we wanted to distinguish
between emigration and cell death. For this purpose, we first
analyzed pro- and anti-apoptotic Bcl-2 family members in cDC
subsets purified 14 h after treatment in vivo with PolyIC, a time
shortly before their depletion (Fig. S3A). Due to the low numbers
of DCs that can be obtained and the clearance of apoptotic cells in
vivo, we examined modulation of Bcl-2 family members at the
mRNA level by quantitative real time (qRT)-PCR, a potential
early apoptotic event (Fig. S3B). Amongst the pro-apoptotic BH3-
only members analyzed, a strong induction of Bim and, albeit to a
lesser extent, Puma could be consistently detected in both cDC
subsets. Of note, CD8a cDCs expressed a higher steady-state level
of Bim (three-fold) and Puma (two-fold) compared to the CD11b
subset (PBS controls). While Noxa displayed inter-experimental
variability in CD8a cDCs, being on average maintained, it was
also up-regulated in CD11b cDCs. Interestingly, Bid expression
was clearly down-regulated with PolyIC in CD8a cDCs, while
CD11b cDCs expressed lower levels in steady-state (PBS) as
compared to CD8a cDCs and maintained these levels after
treatment. In the anti-apoptotic Bcl-2 family members analyzed,
Bcl-xL was clearly increased in both subsets, being in CD8a cDCs
more extensively up-regulated. Bcl-2 was maintained in CD11b
cDCs and slightly down-regulated in CD8a cDCs, while PolyIC
up-regulated Mcl-1, and A1 slightly, in both subsets.
These results show a change in the transcriptional program of
pro- and anti-apoptotic Bcl-2 family members upon PolyIC
treatment, with the strongest induction seen for Bim in both
subsets.
Figure 2. Loss of splenic cDC occurs independently of T, B or NK cells. A. FAS
LPR or perforin
2/2 or control (WT) mice were treated with PBS
(n=3) or PolyIC (n=3) and their splenic cDC analyzed after 40 h. The fold-change in total cells with PolyIC relative to PBS treatment is shown for each
splenic cDC subset. B. Rag2
2/2cc
2/2 and control (WT) mice were injected with PBS (n=3) or PolyIC (n=3), and their splenic DC composition
evaluated as described in Figure S1. The fold-change in total cells with PolyIC relative to PBS treatment is shown. Data are presented as mean +/2 SD.
doi:10.1371/journal.pone.0020189.g002
PolyIC Kills DC via Type I IFN/BH3-Only Proteins
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20189Multiple BH3-only proteins mediate PolyIC-induced
apoptosis of splenic cDC, including but not solely
involving Bim
Further to changes in gene expression, post-transcriptional and
post-translational regulation of certain Bcl-2 family members is a
common event, for instance proteolytic Bid activation. We wanted
to examine whether the mitochondrial apoptotic pathway is
responsible for splenic cDC depletion, and to identify the pro-
apoptotic members possibly involved. To this end, we injected mice
lacking Bim, Puma, Noxa, Bid or combinations of two of these
BH3-only proteins (Puma
2/2Noxa
2/2, Bim
2/2Puma
2/2, Bim
2/2
Noxa
2/2 and Bim
2/2Bid
2/2) with PolyIC and determined their
cDC numbers after 40 h (Fig. 4). These different knock-out mice
displayed normal DC populations (absolute numbers and ‘CD8a
+:
CD8a
2 cDC’ ratio) in steady-state as compared to WT mice (Fig.
S4). Following PolyIC treatment, mice singly deficient for Bid,
Puma or Noxa displayed a reduction in both cDC subsets that was
comparable to that seen in WT mice (Fig. 4C). Remarkably, while
mice lacking Bim showed only a modest protection in cDC, similar
to mice lacking both Puma and Noxa, a striking persistence of cDC
numbers was seen in PolyIC-treated mice lacking Bim and a second
BH3-only protein, either Bid, Puma or Noxa (Fig. 4C). This
protection was already visually striking in the flow cytometric
analysis of cDC subsets (Fig. 4A and B), which showed that the
CD8a cDC subset in particular did not disappear after PolyIC
injection, in contrast to their profound depletion observed in WT
animals.
These results support that apoptosis is responsible for the
depletion of splenic cDC subsets in response to PolyIC, and that
the mechanism requires multiple BH3-only proteins, including
Bim plus either Puma, Noxa or Bid.
Type I IFN is necessary for the induction of splenic cDC
depletion in response to PolyIC
We wanted to identify the signaling events downstream PolyIC
detection that induced DC death. Double-stranded RNA can be
detected by TLR3 in the endosome or by Rig-like Helicases
(MDA-5 and RIG-I) that survey the cytosol compartment and
signal via the adaptor MAVS. PolyIC in particular is a mimic of
long dsRNA (.3 kbp), that may be detected by TLR3 and MDA-
5, but not RIG-I [19]. CD8a cDC are known to express higher
levels of TLR3 than the CD11b subset [4,20] (Fig. S5B). The
expression of MAVS was found to be similar amongst splenic cDC
subsets in WT mice (Fig. S5A). Recent proteomic analysis of DC
subsets has furthermore confirmed such selectively higher levels of
TLR3 in CD8a cDC at the protein level [21]. This might explain
the greater extent of activation, expansion and subsequent
depletion seen in CD8a cDC compared to CD11b cDC.
PolyIC-induced cDC loss was therefore investigated in mice
lacking either Ttlr3 or the adaptor Mavs (downstream of MDA-5)
(Fig. 5). Surprisingly, loss of either Tlr3 or Mavs only resulted in
partially increased persistence of splenic cDC following PolyIC
treatment (Fig. 5A and B). This suggested that apoptosis may be
induced by converging factors downstream dsRNA detection, such
Figure 3. Splenic cDC depletion during infection with LCMV or Leishmania.A .M i c ew e r et r e a t e dw i t hL C M V - W Eo rP B S( c o n t r o l ) .S p l e n i c
cDC activation (CD86 expression) and total cells were analyzed on day 2 (n=3) and day 3 (n=4) (control; n=7). B.M i c ew e r ei n f e c t e dw i t hL.
major or L. guyanensis, or injected with PBS (control). Splenic cDC activation (CD86 expression) and total cells were analyzed on day 3 (n=3)
andday6(n=3)(control;n=4).Dataarepresentedasmean+/2 SD. P-values indicate significance per inoculation compared to injection
with PBS.
doi:10.1371/journal.pone.0020189.g003
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depletion following PolyIC administration was analyzed in mice
lacking the alpha chain of the Type I IFN Receptor (Ifnar1
2/2,
hereafter termed 1IFNR
2/2 mice)
1. Remarkably, loss of 1IFNR
clearly protected both splenic cDC subsets from depletion
following PolyIC treatment (Fig. 5A and B).
TLR3 and MAVS cooperate in IFNß production in
response to PolyIC treatment in vivo
The results showed that production of Type I IFN was the
critical event that caused DC loss in vivo in response to PolyIC.
Deficiency of either TLR3 or MAVS did not protect DC from
PolyIC, suggesting that both TLR3 and MAVS cooperate in Type
Figure 4. Loss of two BH3-only proteins, including Bim, protects cDC subsets from PolyIC-induced depletion. Mice of the genotypes
indicated were injected with PolyIC (n=2 or 3 per strain) or PBS (control; n=2 per strain, except n=1 for Bid
2/2) and splenic cDC numbers determined
after 40 h. A. Strategy for the flow cytometry analysis of splenic cDC subsets. Total splenocytes were gated for CD11c CD45RA
2 (R1), then CD11c
highGr-
1
2 (R2). In order to exclude splenic DC precursors, CD11b cDC were gated as CD8a
2 SIRPa
high cells within the cDC (R1xR2), since fully developed CD11b
cDC express high levels of Sirpa and intra-splenic cDC precursors express only intermediate levels of SIRPa and CD11c [64]. One representative example
of a WT and a Bim
2/2Puma
2/2 mouse injected with either PolyIC or PBS (control) is shown. B. Splenic cDC subset segregation as outlined in (A). One
representative sample is shown per strain and treatment. C. The fold-change in total cells elicited by injection with PolyIC relative to PBS treatment is
shown. Data are represented as mean +/2 SD. P-values indicate significance per mouse strain as compared to WT controls.
doi:10.1371/journal.pone.0020189.g004
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of TLR3 and MAVS in IFNß production in response to PolyIC.
First, systemic production was analyzed in sera of WT, TLR3
2/2,
MAVS
2/2 or 1IFNR
2/2 mice after 4.5 h of PolyIC injection. In
agreement with previous reports [6,22], MAVS was required for
systemic production of this cytokine (Fig. 5C). Secondly, we
analyzed IFNß production by DC. Splenic DC represent a minor
fraction of cells in vivo (e.g. CD8a cDC are 0.25% of total cells in
spleen) and their relative contribution to IFNß production might
not be detectable in serum or cultures of whole splenocytes. We
therefore analyzed DC-rich spleen fractions (containing cDC
subsets, pDC and B cells) as well as purified CD8a or CD11b
subsets. These were obtained from WT, TLR3
2/2, MAVS
2/2 or
1IFNR
2/2 mice and cultured with PolyIC or medium alone for
Figure 5. Type I IFN mediates splenic cDC loss and is cooperatively induced by TLR3 and MAVS in vivo.Aand B.W T ,TLR3
2/2,
MAVS
2/2 and 1IFNR
2/2 mice were treated with PBS (control) or PolyIC. Spleni cc D Cw e r ea n a l y z e da t4 0ha sd e s c r i b e db e f o r e .T h e
segregation of cDC into CD8a a n dC D 1 1 bs u b s e t si ss h o w n( A) for one representative experiment per strain. The fold-change in total cells
with PolyIC relative to PBS treatment is shown (B) for experiments with TLR3
2/2 (n=4) and MAVS
2/2 (n=3) mice with WT mice as controls
(n=4), and for 1IFNR
2/2 (n=3) mice with WT mice as controls (n=3). P-values indicate significance per mouse strain as compared to WT
controls. C.W T ,TLR3
2/2, MAVS
2/2,a n d1IFNR
2/2 mice were injected with PolyIC and the levels of serum IFNb examined 24 h before and
4.5 h after treatment (n=3, representative of two independent experiments). P-values indicate significance comparing PolyIC treatment to
PBS controls, per strain. D. Splenic DC fractions were isolated from WT, TLR3
2/2, MAVS
2/2 and 1IFNR
2/2 mice as depicted in Figure S6 and
cultured in medium (control) or with PolyIC for 4 h. IFNb production was analyzed in supernatants (n=6 for DC-rich fractions, n=5 for cDC
subset fractions, from two independent experiments). P-values indicate significance comparing PolyIC treatment to medium alone, per strain.
Data are presented as mean +/2 SD.
doi:10.1371/journal.pone.0020189.g005
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both the DC-rich fraction and the purified CD8a subset, whereas
the CD11b subset showed no secretion (Fig. 5D). Importantly,
loss of TLR3 abrogated production of IFNß by CD8a cDC, while
MAVS
2/2 CD8a DC showed impaired although still detectable
induction of IFNß (Fig. 5D). These results support that TLR3 and
MAVS cooperate to induce IFNß in response to PolyIC, in a cell-
type specific manner. Isolated splenic CD8a cDC required TLR3,
while other cells relied on MAVS and produced IFNß systemi-
cally. Presumably, the relatively small contribution of splenic
CD8a cDC to systemic IFNß production is not detectable in the
serum of MAVS
2/2 mice.
CD8a DC lines rely on TLR3 for IFNß production and
apoptosis with PolyIC
InadditiontoIFNß productionbyDC,wewanted tovalidate that
DC undergo apoptosis in response to PolyIC, in isolation from other
cells (in vitro), and assess the requirement of TLR3. Of note, several
technical difficulties render the study of DC apoptosis challenging,
includingthescarcityofDCinthemouseandthefactthatdyingcells
are rapidly cleared in vivo (rendering their detection difficult). We
initially assessed whether apoptosis of DC induced by PolyIC
treatment in vivo could be detected by a subsequent enrichment and
4 h culture of DC ex vivo, allowing for phosphatidylserine
translocation (AnnexinV staining) with minimal phagocytosis by
surrounding cells(Fig.S7A).AlthoughaslightincreaseinAnnexinV
staining was seen in cDC from PolyIC-treated mice (Fig. S7B), the
rapid spontaneous activation and apoptosis of splenic cDC ex vivo
(4 h in cDCfrom PBS-treated,Fig.S7Band C)rendered analysisof
PolyIC-induced apoptosis in splenic cDC extremely difficult.
In order to avoid spontaneous apoptosis of DC, we have taken
advantage of novel CD8a DC lines derived from the culture of
tumors arising in our recently reported transgenic mouse model of
Langerhans cell hiostiocytosis [23], harbouring the SV-40LgT
oncogene under the control of the DC-specific CD11c promoter
(Fig. S8A). The DC lines derived share all tested features with
freshly-isolated CD8a DC, such as PAMP-induced up-regulation of
MHC class II and co-stimulation molecules, cytokine secretion
upon activation, and antigen-presentation and cross-presentation
(Fuertes Marraco and Grosjean et al, manuscript in preparation). Following
activation with PolyIC (Fig. S8B), DC lines displayed induction of
apoptosis as confirmed by the standard AnnexinV/7-AAD staining
as well as mitochondrial depolarization (Fig. S8C). Pertinently, the
kinetics of apoptosis in DC lines was reminiscent of the depletion of
splenic cDC observed in response to PolyIC in vivo (Fig. 1).
Several genetically deficient DC lines were derived from tumors
in CD11c:SV40LgT-TG mice crossed to various genetically
deficient backgrounds, including 1IFNR
2/2, TLR3
2/2 and
MAVS
2/2. Upon treatment with PolyIC for 48 h, 1IFNR
2/2 DC
lines were protected from PolyIC-induced apoptosis (Fig. 6A and
B), in agreement with the requirement for the 1IFNR for splenic
cDC loss in vivo (Fig. 5A and B). Strikingly, TLR3
2/2 DC lines
werealsoresistant toPolyIC,whereasMAVS
2/2DClinesremained
normally susceptible (Fig. 6A and B). Importantly, MAVS
2/2 DC
lines produced IFNß in response to PolyIC, whereas the resistance
of TLR3
2/2 DC lines correlated with a lack of IFNß production
(Fig. 6C), in agreement with the requirement of TLR3 for IFNß
production by freshly isolated splenic CD8a cDC (Fig. 5D).
IFNb is sufficient to induce apoptosis of DC lines in vitro
and splenic cDC loss in vivo
We next investigated whether Type I IFN was not only
necessary but also sufficient to induce apoptosis of splenic cDC.
Notably, except for 1IFNR
2/2 DC lines, all other DC lines readily
underwent apoptosis after 48 h of treatment with IFNß, including
the PolyIC-resistant TLR3
2/2 DC lines (Fig. 6A and B). In
addition, effector caspase-3/-7 and initiator caspase-8 activities
were clearly evident in WT DC lines after ,30 h of stimulation
with either PolyIC or IFNß (Fig. 6D).
Further to the preliminary evidence in DC lines, it was critical
to investigate the sufficiency of IFNß to induce loss of splenic cDC
in vivo. Experiments using WT and 1IFNR
2/2 mice showed that
injection of IFNß was sufficient to deplete WT splenic cDC subsets
to an extent similar to that achieved by treatment with PolyIC
(Fig. 7). Moreover, TLR3
2/2MAVS
2/2 double deficient mice
were generated in order to test whether TLR3 and MAVS have a
cooperative action in the loss of splenic cDC in response to PolyIC.
Remarkably, TLR3
2/2MAVS
2/2 splenic cDC were found to be
resistant to PolyIC injection, but remained susceptible to
treatment with IFNß (Fig. 7). These data support the co-operative
action between TLR3 and MAVS in IFNß production in vivo, and
demonstrate that IFNß is alone sufficient to induce splenic cDC
loss in vitro and in vivo.
Discussion
PolyIC kills splenic cDC in vivo, in particular CD8a cDC, via
the conjunction of multiple BH3-only proteins, including
but not solely involving Bim
There are contradictory reports on the effects of microbial
stimulation on DC viability, and to date no reports exist on
apoptotic mechanisms controlling DC populations in vivo. One
prediction is that recognition of pathogens would enhance DC
survival to guarantee potent DC function, thus promoting efficient
adaptive immune responses. Conversely, given the harmful
consequences of exaggerated immune responses, strong microbial
stimulation might be expected to create a need for increased DC
turnover. We show here that splenic cDC undergo apoptosis in
response to PolyIC, particularly affecting the CD8a subset.
Furthermore, loss of splenic cDCs occurred in the absence of T
cells or NK cells, pointing to an apoptotic mechanism that is
intrinsic to DCs and distinct from previous reports [12,13]. In our
hands, concomitant CD40 cross-linking did not rescue CD8a DC
from PolyIC-induced death (data not shown) [24].
Remarkably, while loss of Bim alone afforded only minor
protection of DC, no DC loss was seen in PolyIC-injected mice
lacking Bim plus either Puma, Noxa or Bid. Such correlation
supports that DC apoptosis takes place in vivo in response to
PolyIC. Whether DC that are deficient for two BH3-only proteins
(including Bim) are generally more resistant to apoptosis cannot be
excluded. To test the latter hypothesis, alternative unrelated
treatments that induce apoptosis in splenic cDC would need to be
identified and investigated in the different BH3-only deficient
mice. Of note however, the different mice deficient for BH3-only
members did not display increased DC populations in steady-state
(neither numbers nor CD8a
+-to-CD8a
2 cDC ratio, Fig. S4). This
excludes the presence of abnormally high starting numbers of
splenic cDC in mice deficient for BH3-only members that would
then render DC loss with PolyIC less significant. The involvement
of Bim together with other BH3-only proteins in splenic cDC loss
suggests that it is the overall balance between the pro-apoptotic
BH3-only proteins and the anti-apoptotic Bcl-2 members, which
regulates cDC lifespan after PolyIC stimulation. A similar
overlapping action of several BH3-only proteins has been reported
in neutrophil apoptosis and in the context of inflammatory
arthritis [25,26]. To our knowledge, this is the first report on the
apoptotic mechanism regulating activated DC lifespan in vivo,
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proteins, including but not solely involving Bim.
The CD8a cDC subset is predominantly lost
Intriguingly, in response to PolyIC, LPS and CpG, the CD8a
cDC subset showed greater up-regulation of co-stimulatory
markers (e.g. CD86) and also greater subsequent depletion than
the CD11b subset. Notably, CD8a cDCs displayed a higher
steady-state level of gene expression for Bim, Puma and Bid as
compared to CD11b cDCs (PBS controls), supporting the
hypothesis of a higher intrinsic susceptibility of CD8a cDCs to
apoptosis. Clearly in both subsets, PolyIC treatment further up-
regulated Bim and Puma. Interestingly, CD8a cDC also strongly
up-regulated anti-apoptotic Bcl-xL in response to PolyIC, and
down-regulated pro-apoptotic Bid to the levels of CD11b cDC,
which were maintained upon treatment. This could reflect an
attempt by CD8a cDC to overcome the initially higher pro-
apoptotic to pro-survival Bcl-2 family member ratio than CD11b
cDC, as a negative feedback mechanism in order to temporarily
sustain their activation. The aforementioned results using mice
genetically deficient for pro-apoptotic Bcl-2 family members
nevertheless show that ultimately, in both subsets, Bim with a
second BH3-only protein is sufficient to tilt the pro-to-anti-survival
balance towards cell death. Possible speculations on such
preferential death of the CD8a cDC subset are discussed further
below.
Figure 6. DC lines show TLR3-dependent IFNb secretion with PolyIC and sufficiency of IFNb for apoptosis induction. A and B. WT,
MAVS
2/2, TLR3
2/2 and 1IFNR
2/2 DC lines were cultured in medium, PolyIC, CTRL supernatant or IFNb-containing supernatant (n=3, representative of
at least three independent experiments). AnnexinV/7-AAD staining was performed at 48 h. One representative sample (A) and the fold-change in the
GeoMFI of AnnexinV with treatment (B) are shown. C. Supernatants from WT, TLR3
2/2, MAVS
2/2 and 1IFNR
2/2 DC lines were assayed for IFNb levels
upon treatment with medium or PolyIC for 4 h (n=3 independent experiments). D. WT DC lines were treated with medium, PolyIC, CTRL supernatant
or IFNb-containing supernatant (n=3) for the time-points indicated and analyzed for caspase-3/-7 activity and caspase-8 activity. Data are presented
as mean +/2 SD. Where shown, P-values indicate significance comparing PolyIC treatment to medium alone, per strain.
doi:10.1371/journal.pone.0020189.g006
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DC death, with a cell-type specific and cooperative
involvement of TLR3 and MAVS in vivo
A fundamental question was to dissect the signaling events that
induced apoptosis of DC, and not only their activation, in response
to PolyIC treatment. We show that DC depletion required the
1IFNR, and IFNb was necessary and sufficient to kill DC lines and
deplete splenic cDC in vivo. In our hands, IFNß was predominantly
detected over IFNa in DC culture supernatants (data not shown).
However, whileweaddressedinduction ofDCapoptosis with IFNß,
it cannot be excluded that other members of the Type I IFN family,
notably the different IFNa proteins, may induce similar DC death.
Interestingly, neither endosomal TLR3 nor cytosolic MAVS
were individually indispensable, rather double deficiency (TLR3
2/2
MAVS
2/2) was necessary to prevent DC loss in vivo. In response to
PolyIC, TLR3/TRIF and MDA-5/MAVS signaling axes have
been reported to cooperate in DC activation, antibody production,
as well as CTL and NK responses [6,22,27]. In agreement with the
latter reports [6,22], systemic IFNb production in response to
PolyIC required MAVS. However, we have found that splenic
cDC, in particular the CD8a subset and DC lines, rely on TLR3 for
IFNb production. Such TLR3 requirement in CD8a cDC is in
contrast to a previous report using isolated DEC205+ (CD8a+)D C
[6], where rather MAVS is required. To our knowledge, we provide
first evidence that CD8a cDC rely on TLR3 for IFNß production
and in vitro apoptosis in response to PolyIC, in line with their
characteristic expression of TLR3 [20,21]. Importantly, treatment
with IFNb alone was sufficient induce apoptosis in TLR3
2/2 DC
linesand lossofspleniccDCinmice doublydeficientforbothTLR3
and MAVS.
Our findings support the hypothesis that both TLR3 and
MAVS cooperate in vivo in a cell-type specific manner to produce
IFNb upon PolyIC treatment and consequently splenic cDC loss.
However, different cell types display a differential requirement for
either of these signaling pathways, with systemic IFNß production
depending on MAVS, and splenic CD8a cDC (including DC
lines) requiring TLR3. This furthermore implies that both
autocrine and paracrine Type I IFN production induces DC
death.
Type I IFNs are well recognized anti-viral factors; virtually all
cells may respond to Type I IFN, inducing diverse, and ubiquitous
or cell-type specific effects [28]. Due to the pleiotropic nature of
Type I IFN effects, many of the details of Type I IFN mechanism
of action and their particular relevant scenarios remain to be
elucidated [29]. Inducing an antiviral state, Type I IFNs may
cause growth arrest and apoptosis in several cell types, particularly
in transformed cells. As part of their anti-viral effectiveness, Type I
IFN also induce immune activation, and may further induce
proliferation and sustained survival of certain immune cell types
such as T cells [30].
Induction of Type I IFN by PRR has been recently shown to be
critical for DC function, in particular in the context of the
adjuvant effect of PolyIC [6]. There is however limited evidence
concerning the impact of Type I IFN in DC viability. In vitro, Type
I IFN can antagonize the survival effects of TLR-Ls in fibroblasts
and human MoDC [31], and IFNb induces death in BM-DC
cultures only when they are concomitantly treated with a
stimulatory cocktail [32]. Generally, Type I IFN alone is not
sufficient to induce apoptosis in most cell types [29]. Rather, the
pro-apoptotic effect of Type I IFN generally relies on sensitization
to concomitant apoptotic triggers, such as treatments with TNF
family members [33]. In addition, Type I IFN may itself induce
TNF family members such as TRAIL, and consequently apoptosis
[34], as shown in the context of multiple myeloma. TNFa is
Figure 7. IFNb is sufficient to induce splenic cDC loss in vivo. WT (n = 4), TLR3
2/2 MAVS
2/2 (n=3) or 1IFNR
2/2 (n=4) mice were treated with
PBS, PolyIC, CTRL cells or IFNb-producing cells and the splenic cDC composition was analyzed after 40 h by flow cytometry as described in Figure 1B.
A. The segregation of splenic cDC into CD8a+ or CD11b+ subsets is shown for one representative sample. B. The fold-change in total cells with
treatment relative to PBS controls per cDC subset is shown. Data are presented as mean +/2 SD, from two independent experiments. P-values
indicate significance per treatment as compared to PBS controls, per mouse strain.
doi:10.1371/journal.pone.0020189.g007
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viral infection [35]. Furthermore, the contribution of Bid in
PolyIC-induced DC loss that we observed (Fig. 4) raises the
question of whether death receptor signaling contributes to DC
apoptosis. We therefore tested for a possible involvement of TNFa
or TRAIL in splenic cDC depletion with PolyIC-induced Type I
IFN. Reduction in both cDC subsets with PolyIC still occurred as
extensively in TNFa
2/2 mice (Fig. S9A) or in WT mice treated
with TRAIL-R2:Fc blockade (blocking soluble TRAIL) (Fig.
S9B). Other genetic deficiencies within the TNF or TNF-R
family, including LTa
2/2 or TNFR1
2/2TNFR2
2/2 mice (data
not shown), did not affect the loss of splenic cDC with PolyIC.
Our results show for the first time that IFNb is sufficient to
induce death of splenic cDC in vivo, in absence of accompanying
stimuli, demonstrating a novel apoptotic effect of Type I IFN in a
critical antigen-presenting cell.
What may be the physiological significance of DC death
upon PAMP/Type I IFN stimulation?
Given the critical function of DC for the induction of adaptive
immune responses, the apoptosis of DC in response to a microbial-
like stimulus and/or Type I IFN (critical anti-viral mediators),
affecting in particular the cross-presenting CD8a cDC subset, may
appear paradoxical. Several speculations may be advanced
concerning the physiological significance that such DC death
may have.
DC apoptosis may limit the spread of infection and allow for an
adequate shutdown of immune responses. Critically, DC apoptosis
must maintain a healthy balance between excessive DC clearance
leading to immunosuppression and the maintenance of immune
competence without causing autoimmunity. Aberrant accumula-
tion of DC results in chronic lymphocyte activation and systemic
autoimmune manifestations, as shown in transgenic mice express-
ing the baculoviral pan-caspase inhibitor p35 under the DC-
specific CD11c promoter [9]. Similarly, Bim-deficient DC display
a decrease in spontaneous death in culture and their adoptive
transfer induces autoantibody production in vivo [14]. Conversely,
a reduction in DC numbers has been linked to states of immune
suppression, such as sepsis [36,37] and chronic viral infection.
Impairment of DC function during LCMV infection was reported
and linked to immunosuppressive states, with the LCMV-WE
being more immunosuppressive and persistent than LCMV-
Armstrong [17]. Interestingly, we observed that LCMV-WE
infection causes more extensive cDC depletion than previously
reported for LCMV-Armstrong [16]. Several studies have detected
an impairment of DC function upon TLR stimulation [38],
similarly to chronic inflammatory or infectious states [39,40]. This
has been thought to be a consequence of loss of antigen uptake and
processing in activated DC, but may well (at least in part) have
been due to the here-described DC death.
1IFNR
2/2 mice succumb to infection with many viruses,
showing the importance of Type I IFN for antiviral responses,
including stimulation and clonal expansion of CTL [41,42].
However, a Type I IFN response may also be detrimental under
certain circumstances, such as infection with listeria monocytogenes
[29,43]. While Type I IFN is required for the initiation of
adequate anti-viral responses, the DC apoptosis we report could be
a negative secondary effect of Type I IFN, either when
‘‘inappropriately’’ induced or upon persistent infections. In
support of this idea, persistence of viral infection and immune
suppression has been correlated with reduced DC numbers and
sustained levels of Type I IFN, in models such as LCMV-
Armstrong infection in mice [44], as well as infections with HIV-1
in humans [45] and SIV in monkeys [46]. Collectively, our
findings suggest that one major cause of transient or chronic
immunosuppresion during infectious conditions is a consequence
of apoptotic depletion of DC linked to sustained and/or aberrantly
high Type I IFN levels.
The DC apoptosis we report is particularly relevant for the
therapeutic exploitation of TLR-Ls and Type I IFNs (e.g.
adjuvants, multiple sclerosis, cancer, Langerhans cell histiocytosis)
[2,47,48,49]. Both the adjuvant immune stimulatory and direct
anti-proliferative properties of Type I IFN have a strong potential
for therapeutic exploitation for cancer treatments [50,51].
Similarly, IFNß has been used for the treatment of autoimmune
diseases such as multiple sclerosis [52]. It would be critical to
investigate whether current or developing therapies featuring the
use of Type I IFN or TLR-Ls induce DC loss. Accordingly,
therapeutic regimes should be carefully designed (e.g. dosage,
timing of antigen/adjuvant treatment) in order to avoid the
potentially deleterious side effects of DC apoptosis leading to
immunosuppression.
CD8a DC are particularly potent at phagocytosing dying cells
for antigen cross-presentation and at inducing CTL responses
[53], being thus one key target for vaccines against cancer and
infectious diseases [54,55,56]. Strategies for vaccine enhancement
include the targeting of antigens to CD8a cDC [2,57], for which
PolyIC has been shown to be an optimal adjuvant [2]. Pertinently,
several lines of evidence support that TLR3 expression by CD8a
DC and downstream Type I IFN production is critical for the
adjuvant effect of dsRNA (PolyIC), including cell-associated
dsRNA for cross-presentation [58,59,60,61]. Given the unique
functions of CD8a cDC, their preferential death with a virus-like
stimulus (PolyIC) and Type I IFN (anti-viral mediator), as
compared to the other CD11b DC subset, appears contradictory.
However, on the one hand, apoptosis may be an evolutionary
adaptation to limit the spread of intra-cellular pathogens within
such critical DC subset. On the other hand, apoptosis may serve as
an efficient mechanism to amplify the response to intracellular
pathogens, by an apoptosis-mediated ‘‘DC to DC cross-presenta-
tion’’ of antigens. Via this mechanism, infected cells (DC) would be
sacrificed, while pathogen would be continuously processed and
diluted amongst neighboring cross-presenting DC, correlating
with pathogen load. Such apoptosis-driven ‘‘DC to DC cross-
presentation’’ would be particularly relevant when antigen is
limiting, or considering the naturally low frequency of DC, to
mount an adequate and rapid adaptive immune response.
Perspectives
Future experiments should shed light on the physiological
impact of DC death with PolyIC and Type I IFN. It will be
addressed whether DC death promotes amplification of cross-
presentation, protects from autoimmune pathology, induces side-
effect immunosuppression, and/or affects vaccine efficiency. In
addition to antigen targeting to DC and the use of TLR-Ls as
adjuvants, efforts to optimize vaccine efficacy also include
increasing DC viability after activation [62,63]. Our findings have
the potential to contribute to the optimization of vaccine therapies,
providing an important basis for the design of strategies to enhance
DC viability and consequently function.
Materials and Methods
Ethics statement
Animal experiments were performed in strict accordance to the
Swiss Federal Regulations. The protocol was approved by the
‘‘Service de la consommation et des affaires ve ´te ´rinaires du
Canton de Vaud’’, Switzerland (Permit Number: 1847.1). All
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of mice needed to assess statistical significance and experimental
reproducibility. The generation and use of mouse DC lines for in
vitro research represents a considerable advance towards the
implementation of the 3R (Refine, Reduce, Replace) principle in
animal experimentation.
Mice and treatments
The mice used were females or males aged at least 8 weeks.
Mice were WT (C57BL/6) or Fas
LPR, Perforin (pfn)
2/2, Bim
2/2,
Puma
2/2, Noxa
2/2, Bid
2/2, Puma
2/2Noxa
2/2, Bim
2/2Pu-
ma
2/2
, Bim
2/2Noxa
2/2, Bim
2/2Bid
2/2, Rag2
2/2cc
2/2,
Tlr3
2/2, Mavs
2/2, Tlr3
2/2Mavs
2/2, Ifnar1
2/2, Tnfa
2/2 (see
strain nomenclature, genetic background and references in Table
S1). Mice were injected intra-peritoneally (i.p.) with 50 ug PolyIC
(Poly(I:C)-HMW from Invivogen) or, as a control, with PBS. No
transfecting reagent or liposomal vehicle was used along with
PolyIC. Infection with LCMV-WE consisted of intra-venous (i.v.)
inoculation with 109000 pfu. Systemic infection with Leishmania
was achieved by injection of 20610
6 parasites i.v. and 3610
6
parasites in both hind foot-pads, using infectious stationary phase
promastigotes of either L. major (LV39, MRHO/SU/59/P) or L.
(V.) guyanensis (WHI/BR/78/M5313) strains. Treatment with
IFNß in vivo was performed as described below.
Flow cytometry-based quantitation of splenic cDC
subsets
Splenocyte suspensions were obtained by digestion with
collagenase D (1 mg/mL) and DNAse I (40 ug/mL) in 3% FCS-
RPMI-1640 at 25uC for 30 min. Cell suspensions were passed
through 40 um sieves and washed in PBS containing 5 mM
EDTA and 5 ug/mL DNAse I and then resuspended in PBS
containing 5 mM EDTA and 3% FCS. Total numbers of live
splenic leukocytes were determined by staining with Trypan blue
and counting under a microscope or by using the CasyH cell
counter and analysis system. Fluorochrome-conjugated monoclo-
nal antibodies for flow cytometry were either generated and
conjugated in house or purchased from eBioscience and
BioLegends. Antibodies were specific to CD11c (clone N418,
PECy7, in house or eBioscience), CD45R-B220 (clone RA3-6B2,
PECy5.5, eBioscience), CD45RA (clone 14.8, APC, in house),
GR1/Ly6G (clone RB6-8C5, PE, BioLegends, or biotinylated/
SAVPerCPPECy5.5, in house), CD8a (clone 54-6.7, FITC,
eBioscience, or APC-Cy7, in house), CD11b (clone M1/70,
APC, eBioscience), SIRPa (a.k.a. CD172, clone p84, FITC, in
house), CD40 (clone 1C10, APC, eBioscience), CD80 (clone 16-
10A1, PECy5, eBioscience) and CD86 (clone GL1, APC,
eBioscience). Analyses of Rag2
2/2cc
2/2 splenocytes included
antibodies specific for CD3e (clone 145-2C11, PE, eBioscience),
CD19 (clone 6D5, PECy5.5, eBioscience), and CD49b (clone pan-
NK DX5, FITC, eBioscience). Analysis was performed on Canto
or LSR II machines (Becton Dickinson) using FACSDiva and
FlowJo (Becton Dickinson) for data processing. Total numbers of
cDC subsets were based on the total splenic leukocyte count and
the fractions of cells in each gate used to arrive at a given cDC
subset.
DC isolation, cultures and treatments
The medium composition was IMDM-glutamax (GIBCO
31980) supplemented with 8–10% heat-inactivated FCS, 10 mM
Hepes, 50 uM b-mercaptoethanol, and 50 U/mL of penicillin and
50 mg/mL streptomycin. Cells were cultured at 37uC with 5%
CO2. Different DC populations were obtained from spleens as
depicted in Fig. S6. Briefly, splenocyte suspensions were
fractionated by density centrifugation in isohexol carbohydrate
medium (Nycodenz, Axis-Shield, Norway) at 1.077 g/cm
3 [64].
The DC-enriched, light density fraction was collected as the ‘DC-
rich fraction’ (Fig.S6, fraction 1). Purified cDC subsets (.95%)
were obtained from DC-rich fractions using anti-CD11c antibody-
coupled magnetic micro-beads (Miltenyi Biotech) and flow
cytometry cell sorting of CD11c
+/B220
2 cells into CD8a DC or
CD11b DC (Fig. S6, fraction 2 or 3, respectively) using a
FACSAria cell sorter (Becton Dickinson). DC lines were derived as
detailed in Materials and Methods S1. For apoptosis assays, DC
lines were seeded at 2610
5 cells/mL the day prior and treated
with medium, PolyIC at 5 mg/mL, or CTRL and IFNb-
containing supernatants as detailed below. For IFNß production
assays, supernatants were obtained from DC cultures (DC lines or
DC ex vivo)a t1 0
6 cells/mL treated with medium or PolyIC at
25 ng/mL for 4 h. The PolyIC used was Poly(I:C)-HMW from
Invivogen and no transfecting reagent or liposomal vehicle was
used.
Recombinant IFNß production and treatments
Recombinant murine IFNß was produced in house by lentiviral
transduction of 1IFNR
2/2 DC lines, allowing to obtain a DC-
conditioned medium containing IFNß, in the absence of secondary
effects from the IFNß on the producer cells (see Materials and
Methods S1 for the details). Concentrated IFNß (1–5 ug/mL) was
obtained using high cell density culture systems (CELLine
AD1000, Integra-Biosciences) and diluted to 25 ng/mL of IFNß
for experiments in vitro, with mock-transduced DC line supernatant
used as a control. For treatments in vivo, mice were injected i.p.
with 5610
6 IFNß-producing cells or mock-transduced cells
(CTRL).
IFNb quantitation
IFNb quantitation was performed on cell culture supernatants
or peripheral blood sera by ELISA (PBL 42400, PBL Interferon-
source).
Apoptosis assays
AnnexinV/7-AAD. AnnexinV staining was performed using
fresh AnnexinV-binding buffer (ABB) (14 mM NaCl, 2.5 mM
CaCl2, 10 mM Hepes) containing AnnexinV-PE (BD
Pharmingen) and 7-AAD (eBioscience), both at 1:50, for 15 min
at RT in the dark. All samples were analyzed within 30 min.
Caspase activity assays. The fluorogenic substrates used
were ac-IETD-amc for Caspase-8 and ac-DEVD-amc for
Caspase-3/-7 (Enzo Life Sciences). Caspase-activity assays were
performed on DC line samples according to the manufacturer’s
protocol, measuring caspase-3/-7 activity after 60 min and
caspase-8 activity after 120 min and normalizing data to protein
content quantitated by the standard Bradford reaction.
Statistical analyses
P-values were obtained using two-tailed unpaired t-tests with
95% confidence intervals (ns = not significant; * = p,0.05; ** =
p,0.01; *** = p,0.001).
Supporting Information
Figure S1 Flow cytometry analysis of Rag2
-/-cc
-/- mice
treated with PBS or PolyIC. Rag2
-/-cc
-/- mice were injected i.p.
with 50 ug PolyIC (n=3) or, as a control, PBS (n=3), and their
splenic composition compared to that of similarly treated WT
mice (n=3 for PolyIC, n=3 for PBS). Consistent with previous
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rag2
-/-cc
-/- mice was complicated by the presence of auto-
fluorescent cells. A. Rag2
-/-cc
-/- mice lack B cells, T cells and
NK cells. The autofluorescent cell population in the staining for B
cells, T cells and NK cells is visible on a fluorochrome-empty flow
cytometry channel (FL4). Staining profiles for representative PBS-
treated mice is shown for each strain. B. Gating strategy for the
analysis of splenic cDC, excluding pDC, monocyte-derived DC
and autofluorescent cells by a first gate on GR1 and B220 double-
negative cells (an additional flow cytometry channel was not
available in the staining combination for cDC analysis). CD11c
+
cells from the GR1
2B220
2 were selected for segregation into
CD8a
+ vs CD11b
+ subsets. Data from one representative mouse
for each strain and treatment is shown. C. Total numbers of each
cDC subset were calculated on the basis of total splenocytes
harvested multiplied by the fraction of cells per gate as indicated in
(b). To obtain the fold-changes in the cDC subset cellularities
elicited by injection with PolyIC, the total number of DC in the
spleens of mice treated with PolyIC were divided by the total
number of DC in the spleens of PBS-treated mice. P-values
indicate significance per strain as compared to WT controls.
(TIF)
Figure S2 Loss of splenic cDC after CpG and LPS
injection. Mice (C57BL6) were injected i.p. with PBS (control;
n=4), 50 ug of CpG (n=3), 10 ug of LPS (n=3) or, as
comparison to data shown in Figure 1, with 50 ug PolyIC (n=1).
Splenic cDC subsets were analyzed at 12 h post-injection for
expression of the activation marker CD86 (GeoMFI = geometric
mean of fluorescence intensity) and at 40 h for total numbers of
cDC subsets. P-values indicate significance per treatment com-
pared to injection with PBS.
(TIF)
Figure S3 Changes in gene expression of Bcl-2 family
members in cDC treated with PolyIC in vivo. Mice were
injected with50ugPolyIC(n=9)orPBS(control;n=9).After14h,
the spleens were harvested and pooled for cDC subset isolation and
gene expression analysis. The experiment was performed twice in
two independent laboratories as described in the Methods section,
with a total of four biological replicates per sample. a. Strategy for
flow cytometric analysis, gating and isolation of CD8a or CD11b
cDC subsets from total splenocytes. One representative experiment
is shown. b. Analysis of the levels of mRNA for pro-apoptotic Bcl-2
family members Bim (n=4), Puma (n=4), Noxa (n=4), Bid (n=3)
and anti-apoptoticBcl-2 (n=4),Mcl-1(n=4),A1 (n=3)andBcl-xL
(n=3). Open symbols (#, e) correspond to qRT-PCR data
generated at the WEHI (Melbourne), normalized to b-actin as a
house-keeping gene. Closed symbols (N, ¤) correspond to qRT-PCR
data generated at the DB-UNIL (Lausanne), normalized to TBP as
a house-keeping gene. The primers used were as detailed in Table
S2A. In order to obtain an inter-experimental and inter-laboratory
comparison, a second normalization was performed relative to
CD8a cDCs treated with PBS.
(TIF)
Figure S4 Steady-state splenic cDC populations in mice
deficient for BH3-only members. Splenic cDC subsets were
quantitated as described before amongst WT (n=6), Bim
-/- (n=4),
Puma
-/- (n=2), Noxa
-/- (n=4), Bid
-/- (n=3), Puma
-/-Noxa
-/- (n=2),
Bim
-/-Puma
-/- (n=2), Bim
-/-Noxa
-/- (n=4), Bim
-/-Bid
-/- (n=2). A.
Ratio of CD8a
+-to-CD8a
2 cDC per mouse strain as indicated. B.
Total numbers of each cDC subset per spleen per mouse strain as
indicated. Data are represented as mean +/- SD. P-values indicate
significance per strain as compared to WT controls.
(TIF)
Figure S5 Expression levels for TLR3, MAVS and the
IFNaR1 in splenic cDC subsets and DC lines. Purified
splenic CD8a as well as CD11b cDC subsets and DC line
samples (n=2 per sample) were examined for the levels of mRNA
for Mavs and Ifnar1 by qRT-PCR using the primers detailed in
Table S2B. Tlr3 mRNA expression was analyzed by semi-
quantitative PCR.
(TIF)
Figure S6 Strategy and flow cytometry analysis for the
purification of DC-rich and cDC subset fractions.
Splenocyte suspensions were fractionated by density centrifugation
in isohexol carbohydrate medium (Nycodenz, Axis-Shield, Nor-
way) at 1.077g/cm3. The light density fraction was collected as the
DC-rich fraction (fraction 1, as indicated). CD11c+ cDC were
isolated from DC-rich fractions using anti-CD11c antibody
coupled magnetic micro-beads (Miltenyi Biotech). Purified cDC
subsets were obtained from cDC by flow cytometry cell sorting
separating CD11c
+/B220
2 cells into CD8a or CD11b subsets,
collecting fractions 2 and 3, respetively, as indicated. One
representative sample is shown. The cDC represent 1-2% of total
splenic leukocytes. Within the cDC population, typically ,20%
were CD8a
+ cDC and ,60% CD11b cDC. At least 5 mice were
required to isolate ,0.5610
6 CD8a
+ cDC. Density centrifugation
allowed for a ,10-fold enrichment in DC prior to immunomag-
netic bead selection. Enriched DC preparations subjected to flow-
cytometric cell sorting contained .75% cDC, and resulting cDC
subsets were purified to at least 95%.
(TIF)
Figure S7 Activation and apoptosis in splenic cDC ex-
vivo, isolated from either PBS- or PolyIC-treated mice.
A. Experimental outline. Briefly, WT mice (n=2) were treated
with PBS or PolyIC for 24h. Splenic cDC were enriched by
density centrifugation and analyzed inmediately (‘‘0h’’) or after 4h
of culture (‘‘4h’’). Analysis included the segregation of cDC subsets
as before and the apoptosis staining AnnexinV (B) or the
activation marker CD86 (C). Data are represented as mean +/-
SEM.
(TIF)
Figure S8 PolyIC induces activation and apoptosis in
DC lines. A. Phenotype of DC lines derived from
CD11c:SV40LgT-transgenic mice (NB. harbouring the eGFP
reporter for the transgene) [23], analyzed by flow cytometry and
compared to splenic cDC in WT mice as indicated. B and C.D C
lines (WT) were treated in vitro with 8 ug/mL poly I:C. B.
Histograms showing the up-regulation of co-stimulatory markers
CD40, CD80 and CD86 at 24 h of treatment with PolyIC (dark
grey) as compared to unteated controls (pale grey). C. The kinetics
of poly I:C treatment are shown for a representative experiment,
with flow cytometry analysis of FSC vs SSC plots, AnnexinV/7-
AAD double-staining and TMRM histograms at different time
points as indicated.
(TIF)
Figure S9 Splenic cDC loss with PolyIC still occurs in
TNFa-/- mice or with TRAIL-R2:Fc blockade. A. WT and
TNFa
-/- mice were treated with PBS (control) or PolyIC and
splenic cDC were analyzed at 40 h as described before (n=2 per
treatment per mouse strain). The fold-change in total cDC subset
cells with PolyIC relative to PBS treatment is shown per strain as
indicated. B. WT mice were treated with PBS or TRAIL-R2:Fc
6h before and at 18h after treatment with either PBS or PolyIC
(time 0h) and splenic cDC were analyzed at 40 h as described
before (n=2 per treatment). Total numbers of each cDC subset
PolyIC Kills DC via Type I IFN/BH3-Only Proteins
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mean +/- SD.
(TIF)
Materials and Methods S1 Materials and Methods used
for the experiments shown in Supporting Figures and
related to Materials and Methods.
(DOC)
Table S1 Mouse strains used (related to Materials and
Methods and Materials and Methods S1).
(DOC)
Table S2 Primers used for gene expression analyses
(related to Materials and Methods S1).
(DOC)
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